repotrectinib
Bms
['trident-1', 'trident', 'nsclc', 'sclc', 'repotrectinib']
explore &amp; 's results of phase 1/2 trident-1, investigating efficacy of repotrectinib in nsclc &amp; central nervous system metastases at 4:30pm cdt: #crukfunded #asco23 
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK